SCHEMBL3020756

SCHEMBL3020756

Cc1ccccc1-c1csc(N2CCN(S(=O)(=O)c3ccc(Cl)cc3Cl)CC2)n1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AR P10275 2/20 0.49
LMNA P02545 3/20 0.47
MEN1 O00255 2/20 0.47
KMT2A Q03164 2/20 0.47
MAPK1 P28482 2/20 0.47
SMN1; SMN2 Q16637 3/20 0.46
MAPT P10636 3/20 0.46
ALDH1A1 P00352 2/20 0.46
TRPV4 Q9HBA0 1/20 0.46
HSD11B1 P28845 2/20 0.44
L3MBTL1 Q9Y468 1/20 0.43
NPSR1 Q6W5P4 2/20 0.42
USP2 O75604 1/20 0.42
RECQL P46063 1/20 0.42
HSD17B10 Q99714 1/20 0.42
LPAR1 Q92633 1/20 0.42
LPAR2 Q9HBW0 1/20 0.42
KDM4E B2RXH2 1/20 0.40
POLB P06746 1/20 0.40
TSHR P16473 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3012852 0.92 AR (0.47) ARLMNAMEN1KMT2AMAPK1
SCHEMBL3019200 0.92 MEN1 (0.47) ARLMNAMEN1KMT2AMAPK1
SCHEMBL3010509 0.90 SMN1; SMN2 (0.54) ARLMNAMEN1KMT2AMAPK1
SCHEMBL3018270 0.90 MEN1 (0.46) ARLMNAMEN1KMT2AMAPK1
SCHEMBL3002043 0.90 KMT2A (0.52) ARLMNAMEN1KMT2AMAPK1
SCHEMBL3015256 0.89 AR (0.57) ARLMNAMEN1KMT2AMAPK1
SCHEMBL3015903 0.89 MAPT (0.47) ARLMNAMEN1KMT2AMAPK1
SCHEMBL3022481 0.89 LMNA (0.48) ARLMNAMEN1KMT2AMAPK1
SCHEMBL3014366 0.88 ALDH1A1 (0.52) LMNAMEN1KMT2AMAPK1MAPT
SCHEMBL3010342 0.87 MAPT (0.48) ARLMNAMEN1KMT2AMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2188272-B1 PHENYL- AND BENZYLTHIAZOLYLPIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES REMYND NV (BE) 2016-02-24 EP disclosed
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA AR 3801/4885LMNA 80/4885MEN1 454/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.